Skip to main content
Swing Capital

Amrutanjan Health Care Ltd

NSE: AMRUTANJAN BSE: 590006

AHCL has been manufacturing ayurvedic balm for pain management since 1893, and is currently managed by the third-generation of promoters. The company is more than 120 years old and is into OTC products in the segments of pain management, women's hygiene, and packaged fruit juice drink. [1]

₹556
52W: ₹486 — ₹791
PE 25 · Book ₹128 · +334% vs book
Market Cap₹1,608 Cr
Stock P/E25Price to Earnings
ROCE24.8%Return on Capital
ROE18.5%Return on Equity
Div. Yield0.81%Face Value ₹1

Strengths

  • +Company is almost debt free.
  • +Company's working capital requirements have reduced from 123 days to 96.0 days

Weaknesses

  • −The company has delivered a poor sales growth of 8.59% over past five years.
  • −Promoter holding has decreased over last 3 years: -3.52%

Shareholding Pattern

Promoters46.52%
FIIs2.17%
DIIs12.66%
Public38.61%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters50.58%46.52%▼4.146.52%46.52%46.52%46.52%46.52%46.52%
FIIs1.55%2.34%▲0.82.3%▼0.02.3%2.41%▲0.12.38%▼0.02.27%▼0.12.17%▼0.1
DIIs7.32%10.6%▲3.311.13%▲0.511.41%▲0.312.7%▲1.312.9%▲0.213%▲0.112.66%▼0.3
Public40.47%40.5%▲0.040.01%▼0.539.75%▼0.338.34%▼1.438.16%▼0.238.18%▲0.038.61%▲0.4

Financial Statements

MetricDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales1171278411012313594118141150
Expenses9511180969911886101116124
Operating Profit221641423188172526
OPM %18%13%4%12%19%13%9%14%18%17%
Net Profit171451219158141916
EPS ₹6.044.721.64.086.665.252.874.836.735.6

AI Insights

Revenue Trend

Mar 2026 revenue at ₹503Cr, up 11.3% YoY. OPM at 15%.

Debt Position

Borrowings at ₹2Cr. Debt-to-equity ratio: 0.01x. Healthy balance sheet.

Capex Cycle

CWIP at ₹105Cr (206% of fixed assets). Significant capex underway — growth runway building.

Institutional Flow

DIIs: 12.66% (+5.44pp change). FIIs: 2.17% (+1.48pp change). Promoters hold 46.52%.

Margin & Efficiency

ROCE declining from 26% (Mar 2015) to 25% (Mar 2026). Working capital days: 96.

Valuation

PE 25x with 24.8% ROCE. Price is 334% above book value of ₹128. Dividend yield: 0.81%.

Recent Announcements